

MARKED VERSION OF AMENDED CLAIMS - 33827-US-009

2. Compounds of the formula I according to [Claim] claim 1, in which
- A denotes a benzo ring,
 - X¹ denotes O, and
 - R¹ denotes hydrogen.
3. Compounds of the formula I according to claim 1 [Claim 1 or 2], in which
- B denotes phenyl, cyclohexyl, piperidine, pyridine, pyrimidine, pyrrole, pyrazole, thiophene, furan, oxazole, naphthalene, piperazine, quinoline, pyrazine or indole, each of which can be substituted by one R⁴ or at most 2 R⁵.
4. Compounds of the formula I according to claim 1 [at least one of Claims 1 to 3], in which
- L denotes a carbon chain which has from 1 to 8 C atoms and which contains at least one triple bond, where the carbon atoms of the chain can be substituted by one or two R⁴ radicals and at most two different or identical R⁵ radicals,
 - v denotes 1, and
 - w denotes 0 or 1.
5. Compounds of the formula I according to claim 1 [at least one of Claims 1 to 4], in which
- R⁴ denotes D_{0,1}-F¹_{0,1}-G²-G³, where G³ denotes hydrogen,
 - D denotes O or NR⁴³, where R⁴³ denotes hydrogen or C₁-C₃-alkyl, and

MARKED VERSION OF AMENDED CLAIMS - 33827-US-009

F¹ denotes C₂-C₄-alkyl.

6. Compounds of the formula I according to claim 1 [at least one of Claims 1 to 4],
in which

R⁴ denotes G¹-F¹₀, -G²-G³, where G³ denotes hydrogen, and

F¹ denotes C₁-C₂-alkyl.

7. Compounds of the formula I according to [Claim] claim 6, in which

G¹ denotes imidazole or pyrrole, where the pyrrole can in each case be
substituted by at most three different or identical R⁵ radicals, and

F¹ denotes C₁-C₂-alkyl.

8. Pharmaceutical composition which comprises at least one compound according
to claim 1 [one of Claims 1 to 7] and also at least one customary carrier and/or
auxiliary substance.


9. Use of a compound of formula I according to claim 1 [one of Claims 1 to 7] for
producing a pharmaceutical for the prophylaxis and/or treatment of
neurodegenerative diseases, neuronal damage or damage due to ischaemias,
for treating microinfarctions, for treating in association with a revascularization of
critically stenosed coronary arteries or critically stenosed peripheral arteries, for
treating acute myocardial infarction and damage during and after its medicinal or
mechanical lysis, for treating tumours and their metastases, and for treating
sepsis, multiorgan failure, immunological diseases, diabetes mellitus and viral
infections.

MARKED VERSION OF AMENDED CLAIMS - 33827-US-009

10. Process for the prophylaxis and/or treatment of neurodegenerative diseases, neuronal damage or damage due to ischaemias, for treating microinfarctions, for treating in association with a revascularization of critically stenosed coronary arteries or critically stenosed peripheral arteries, for treating acute myocardial infarction and damage during and after its medicinal or mechanical lysis, for treating tumours and their metastases, and for treating sepsis, multiorgan failure, immunological diseases, diabetes mellitus and viral infections by administration of an effective quantity of at least one compound of the formula I according to claim 1 [one of Claims 1 to 7].
11. Process for producing a compound according to claim 1 [one of Claims 1 to 7], which comprises condensing an aldehyde of the formula II with a diamine of the formula III:



(II)




(III)

where the symbols in the formulae II and III have the same meaning as in claim [Claim] 1.

12. Process according to claim [Claim] 11, where the diamine of the formula III is

MARKED VERSION OF AMENDED CLAIMS - 33827-US-009

obtained by reacting a substituted nitrobenzoic ester of the formula IV with a diamine of the formula V, in a polar solvent and in the presence of a base, and subsequently hydrogenating:



where the symbols in the formulae IV and V have the same meaning as in Claim 1 and R^2 denotes branched or unbranched, saturated or unsaturated C_1 - C_6 -alkyl.